홈 › 만성 림프구성 백혈병 › 조지아
조지아의 만성 림프구성 백혈병 임상 시험
만성 림프구성 백혈병 관련 연구 16개가 조지아 내 여러 지역에서 참여자를 모집하고 있습니다.
조지아의 도시
공식 연구 텍스트(영어)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Northeast Georgia Medical Center Braselton, Braselton
- Atlanta VA Medical Center, Decatur
- Northeast Georgia Medical Center-Gainesville, Gainesville
- 외 4개
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT05334069A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Augusta University, Augusta
- Southeastern Regional Medical Center, Newnan
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT05006716A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Emory University Winship Cancer Institute, Atlanta
- Northside Cancer Center, Atlanta
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06846671Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Winship Cancer Institute Emory University, Atlanta
- Northside Hospital Cancer Institute, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT03666000Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope - Atlanta, Newnan
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT04588922Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Central Georgia Cancer Care, Macon
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 31. 업데이트됨 · NCT07516093A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Northside Hospital, Atlanta
피험자 모집 중1상건강한 지원자 환영
18세 ~ 75세 · 모든 성별 · 2026. 7. 28. 업데이트됨 · NCT07020533Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT03501576A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Winship Cancer Institute of Emory University, Atlanta
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 2. 업데이트됨 · NCT05131022A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- City of Hope National Medical Center, Atlanta Cancer Center, Newnan
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 5. 19. 업데이트됨 · NCT06588478Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- City of Hope Atlanta Cancer Center, Newnan
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 3. 13. 업데이트됨 · NCT07218510CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- Northside Hospital, Atlanta
피험자 모집 중2상건강한 지원자 환영
18세 ~ 75세 · 모든 성별 · 2026. 3. 10. 업데이트됨 · NCT06059391A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- The Emory Clinic, Atlanta
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 3. 2. 업데이트됨 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- The Emory Clinic, Atlanta
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 3. 2. 업데이트됨 · NCT06876649Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Winship Cancer Institute of Emory University /ID# 230643, Atlanta
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 2. 9. 업데이트됨 · NCT04895436Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
- Winship Cancer Institute at Emory University, Atlanta
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 1. 7. 업데이트됨 · NCT06043674ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.